ALSO NOTED: ImaRx prices IPO; Sepracor, Eisai sign deal for Lunesta; and much more...

> GSK has decided not to exercise its option to license Exelixis' non-small cell lung cancer drug XL647 for further development. Release

> ImaRX Therapeutics has priced its IPO at $5 per share. Release

> Chutes & Ladders: Silence Therapeutics has appointed Jeffery Scott Vick as Group CEO. Release

> Sepracor and Eisai have signed a deal development and commercialization of Sepracor's sleep drug Lunesta for the Japanese market. Release

And Finally... According to a Wake Forest University School of Medicine study, a class of drugs (which included Avandia and Actos) used to treat type 2 diabetes may double the risk of heart failure. Report

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.